Detail page

Knowledge Web

Person

Martin Sebastian (1965-)

Name	Martin Sebastian
Time	1965- (Date of birth and death)
Further information	Facharzt für Innere Medizin, Pneumologie, Intensivmedizin
Record type	Person
GND-Identifier	129885916
Record ID	129885916
Involved in show all Immuntherapien beim frühen NSCLC : (Neo-)adjuvante und perioperative Ansätze erweitern das Feld Status epilepticus in patients with brain tumors and metastases: A multicenter cohort study of 208 patients and literature review Evolutionary trajectories of small cell lung cancer under therapy Multicenter real-world analysis of combined MET and EGFR inhibition in patients with non-small cell lung cancer and acquired MET amplification or polysomy after EGFR inhibition Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in Germany Favorable survival outcomes in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer sequentially treated with a tyrosine kinase inhibitor and osimertinib in a real-world setting Lung cancer resection after immunochemotherapy vs. chemotherapy in oligometastatic NSCLC An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms : Interdisziplinäre S3-Leitlinie der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin und der Deutschen Krebsgesellschaft – Kurzfassung Evaluation of the effectiveness of a nationwide precision medicine program for patients with advanced non-small cell lung cancer in Germany: a historical cohort analysis Machine-learning-aided prediction of brain metastases development in non–small-cell lung cancers Survival benefit with checkpoint inhibitors versus chemotherapy is modified by brain metastases in patients with recurrent small cell lung cancer State of the Art: onkogen alteriertes nichtkleinzelliges Lungenkarzinom im Stadium IV Clinical predictors of survival in patients with relapsed/refractory small-cell lung cancer treated with checkpoint inhibitors: a German multicentric real-world analysis Clinical predictors of survival in patients with relapsed/refractory small-cell lung cancer treated with checkpoint inhibitors: a German multicentric real-world analysis Immune checkpoint inhibitor-induced cerebral pseudoprogression: patterns and categorization Pulmonary resection after radiosurgery and neoadjuvant immunochemotherapy for NSCLC patients with synchronous brain metastasis — a case series of three patients Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM) A randomized, multicenter phase II study comparing efficacy, safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancer Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315) Corrigendum to "Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP registry (AIO-TRK-0315)" [Lung Cancer 152 (2021) 174–184] Corrigendum to “Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP registry (AIO-TRK-0315)” [Lung Cancer 152 (2021) 174–184] KRAS mutations in squamous cell carcinomas of the lung Two-year survival with nivolumab in previously treated advanced non–small-cell lung cancer: a real-world pooled analysis of patients from France, Germany, and Canada Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315) Colonization with multi-drug-resistant organisms negatively impacts survival in patients with non-small cell lung cancer A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer Efficacy and safety analysis of the German expanded access program of osimertinib in patients with advanced, T790M-positive non-small cell lung cancer Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer ROS1 rearrangements in lung adenocarcinoma : prognostic impact, therapeutic options and genetic variability Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer First-line treatment of EGFR-mutated nonsmall cell lung cancer : critical review on study methodology Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer Unspunnenfest : Steinstossen und Schwingen, Trachtentanz und Folklore, Tourismus und Schweizer Geschichte ; 1805 bis heute Immunologische Aktivierungsparameter bei Patienten mit nicht-kleinzelligem Lungenkarzinom unter Therapie mit dem bispezifischen Antikörper Removab

Please note

The beta version does not yet contain all functions and information of the DNB portal catalogue. If you are missing information or want to order a medium, please visit the page in the DNB portal catalogue via the following link:

Katalog der Deutschen Nationalbibliothek

Martin Sebastian (1965-)

Immuntherapien beim frühen NSCLC : (Neo-)adjuvante und perioperative Ansätze erweitern das Feld

Status epilepticus in patients with brain tumors and metastases: A multicenter cohort study of 208 patients and literature review

Evolutionary trajectories of small cell lung cancer under therapy

Multicenter real-world analysis of combined MET and EGFR inhibition in patients with non-small cell lung cancer and acquired MET amplification or polysomy after EGFR inhibition

Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in Germany

Favorable survival outcomes in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer sequentially treated with a tyrosine kinase inhibitor and osimertinib in a real-world setting

Lung cancer resection after immunochemotherapy vs. chemotherapy in oligometastatic NSCLC

An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms : Interdisziplinäre S3-Leitlinie der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin und der Deutschen Krebsgesellschaft – Kurzfassung

Evaluation of the effectiveness of a nationwide precision medicine program for patients with advanced non-small cell lung cancer in Germany: a historical cohort analysis

Machine-learning-aided prediction of brain metastases development in non–small-cell lung cancers

Survival benefit with checkpoint inhibitors versus chemotherapy is modified by brain metastases in patients with recurrent small cell lung cancer

State of the Art: onkogen alteriertes nichtkleinzelliges Lungenkarzinom im Stadium IV

Clinical predictors of survival in patients with relapsed/refractory small-cell lung cancer treated with checkpoint inhibitors: a German multicentric real-world analysis

Clinical predictors of survival in patients with relapsed/refractory small-cell lung cancer treated with checkpoint inhibitors: a German multicentric real-world analysis

Immune checkpoint inhibitor-induced cerebral pseudoprogression: patterns and categorization

Pulmonary resection after radiosurgery and neoadjuvant immunochemotherapy for NSCLC patients with synchronous brain metastasis — a case series of three patients

Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM)

A randomized, multicenter phase II study comparing efficacy, safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancer

Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315)

Corrigendum to "Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP registry (AIO-TRK-0315)" [Lung Cancer 152 (2021) 174–184]

Corrigendum to “Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP registry (AIO-TRK-0315)” [Lung Cancer 152 (2021) 174–184]

KRAS mutations in squamous cell carcinomas of the lung

Two-year survival with nivolumab in previously treated advanced non–small-cell lung cancer: a real-world pooled analysis of patients from France, Germany, and Canada

Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315)

Colonization with multi-drug-resistant organisms negatively impacts survival in patients with non-small cell lung cancer

A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer

Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer

Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer

Efficacy and safety analysis of the German expanded access program of osimertinib in patients with advanced, T790M-positive non-small cell lung cancer

Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer

ROS1 rearrangements in lung adenocarcinoma : prognostic impact, therapeutic options and genetic variability

Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer

First-line treatment of EGFR-mutated nonsmall cell lung cancer : critical review on study methodology

Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer

Unspunnenfest : Steinstossen und Schwingen, Trachtentanz und Folklore, Tourismus und Schweizer Geschichte ; 1805 bis heute

Immunologische Aktivierungsparameter bei Patienten mit nicht-kleinzelligem Lungenkarzinom unter Therapie mit dem bispezifischen Antikörper Removab